Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

LPCN Relative to the S&P 500

LPCN Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Lipocine Inc. (NASD:LPCN) seasonal charts above shows that a Buy Date of December 12 and a Sell Date of March 1 has resulted in a geometric average return of 5.52% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 50.93% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company’s product TLANDO is an oral testosterone replacement therapy (“TRT”). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

To download LPCN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: LPCN